Hui Du

Hui Du

Auto-generated profile, based on publicly available information

Hui Du

Department of Chemical Engineering

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
HDHui Du
Hui Du
HTHoang Trinh
Hoang Trinh
Olivia C BrandonOlivia C Brandon
Olivia C Brandon
RZRenyu Zheng
Renyu Zheng
HWHaoyu Wang
Haoyu Wang
ENElizabeth Nance
Elizabeth Nance
Acute brain injuries such as perinatal asphyxia, stroke, and traumatic brain injury result in ischemia, oxidative stress, excitotoxicity, and inflammation, leading to a depletion of ATP, the brain’s cellular energy store. Nicotinamide adenine dinucleotide (NAD+), a key regulator of cellular homeostasis, is crucial for energy regeneration and DNA repair in post-injury recovery. However, the therapeutic benefits of NAD+ and its precursors, such as nicotinamide (NAM), are limited by the complexity of their metabolic pathways and challenges in effective cell-specific intracellular delivery. Therefore, cellular delivery strategies are needed to capture the potential of an NAD+-regenerating therapeutic approach. In this study, we introduce a nanopeptoid delivery strategy to replenish cellular redox state and energy production in the acutely injured brain. By self-assembling peptoids into tubular structures, we created biocompatible NAM-conjugated peptoid nanotubes (NAM-PNTs) that vary in tubular length. NAM-PNTs demonstrated significant therapeutic benefits by enhancing cell viability and replenishing intracellular ATP levels within 24 hours of treatment in oxygen-glucose deprived (OGD) BV-2 cells. In organotypic brain slices, NAM-PNT treatment promoted glial proliferation, reduced pro-inflammatory cytokine levels, and increased anti-inflammatory cytokines after OGD, an ex vivo model of hypoxia-ischemia. A single systemic dose of NAM-PNTs also reduced brain tissue loss and improved neuropathology after hypoxia-ischemia in term-equivalent rats. These findings highlight the strong therapeutic potential of NAM-PNTs for cell-specific targeted delivery and energy restoration in the acutely injured neonatal brain. In the neonatal brain injury field, this is the first demonstration of a novel nanoparticle platform development from first principles design and synthesis to in vitro screening and then demonstration of efficacy in vivo.

13 April 2026 in ACS Nano
Verified
Journal Article
Open access
HDHui Du
Hui Du
TTThi Kim Hoang Trinh
Thi Kim Hoang Trinh
OBOlivia C. Brandon
Olivia C. Brandon
RZRenyu Zheng
Renyu Zheng
HWHaoyu Wang
Haoyu Wang
ENElizabeth Nance
Elizabeth Nance
Acute brain injuries such as perinatal asphyxia, stroke, and traumatic brain injury result in ischemia, oxidative stress, excitotoxicity, and inflammation, leading to a depletion of ATP. Nicotinamide adenine dinucleotide (NAD+) is crucial for ATP regeneration and DNA repair during postinjury recovery. However, the therapeutic benefits of NAD+ and its precursors, such as nicotinamide (NAM), are limited by challenges in achieving effective cell-specific intracellular delivery. In this study, we use a nanopeptoid delivery strategy to replenish the cellular redox state and increase energy production in the acutely injured brain. By self-assembling peptoids into tubular structures, we created biocompatible NAM-conjugated peptoid nanotubes (NAM-PNTs) that vary in tubular length. NAM-PNTs demonstrated significant therapeutic benefits by enhancing cell viability and replenishing intracellular ATP levels within 24 h of treatment in oxygen-glucose-deprived (OGD) BV-2 cells. In organotypic brain slices, NAM-PNT treatment promoted glial proliferation, reduced proinflammatory cytokines, and increased anti-inflammatory cytokines after OGD, an ex vivo model of hypoxia-ischemia. The effect of NAM-PNTs is associated with their uptake into microglia via fluid-phase phagocytosis and caveolae-mediated endocytosis. A single systemic dose of NAM-PNTs localized in microglia in the injured hemisphere and reduced brain tissue loss and improved neuropathology after hypoxia-ischemia in term-equivalent rats. These findings highlight the therapeutic potential of NAM-PNTs for cell-specific targeted delivery and energy restoration in the acutely injured neonatal brain. In the neonatal brain injury field, this work demonstrates the development of an innovative nanoparticle platform from first-principles design and synthesis to in vitro screening and then demonstration of efficacy in vivo.